Clinical Trial

A Study to Evaluate MAR002 for Acromegaly

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-08.
Trial Details
NCT Number NCT07641179
Lead Sponsor Marea Therapeutics
Conditions Acromegaly
Enrollment 72 participants
Start Date 2026-07
Primary Completion 2027-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12